The UW Program for Advanced Cell Therapy has completed enrollment for the pilot MARSH (Marrow-derived Autologous Stromal cells for the Restauration of Salivary Hypofunction) clinical trial.
Six patients with radiation-induced Xerostomia (Dry Mouth) were treated in the pilot study led by Randall Kimple. The therapy delivers a single dose of GMP-manufactured, autologous Interferon gamma-stimulated bone marrow-derived mesenchymal stromal cells (MSCs) delivered “fresh” into one submandibular salivary gland.
Results from the study will be used to inform the safety and tolerability for feasibility of a UW Program for Advanced Cell Therapy-sponsored Phase 1, dose escalation clinical trial that includes 24 to 30 additional patients. Salivary gland function will be used to evaluate efficacy.
See (https://lnkd.in/gG7YqfTt) for details.